CS
TRVI icon

Credit Suisse’s Trevi Therapeutics TRVI Stock Holding History

Credit Suisse’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,374
Closed -$16K – 4133
2022
Q3 		$16K Buy
+10,374
New +$34K ﹤0.01% 3601

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Credit Suisse's TRVI Position: Q4 2022 in Review

Credit Suisse sold out of Trevi Therapeutics (TRVI) in Q4 2022, closing a stake of 10,374 shares — an estimated $16K sold.

Credit Suisse first reported a position in TRVI in Q3 2022 and held it in 1 quarter. The position peaked at $16K in Q3 2022. 37 funds tracked by Wall St. Rank hold TRVI as of Q4 2022.

  • Credit Suisse reported no remaining Trevi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Credit Suisse sold 10,374 Trevi Therapeutics shares in Q4 2022, an estimated $16K.
  • Credit Suisse first reported a position in Trevi Therapeutics in Q3 2022 and held it in 1 quarter.
  • Credit Suisse's Trevi Therapeutics position peaked at $16K in Q3 2022.
  • 37 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.